Tag: apolipoprotein(a)
-
Novartis’ Pelacarsen Fails Phase 3 Lp(a)HORIZON Despite Lowering Lp(a)
Novartis and Ionis reported that pelacarsen lowered Lp(a) but failed to significantly reduce 4-point MACE in the Phase 3 Lp(a)HORIZON trial, raising new questions about the clinical validity of Lp(a) lowering.
-
Why Lowering Lp(a) Wasn’t Enough: What Pelacarsen’s Phase 3 Failure Means
Pelacarsen targets LPA mRNA to reduce apo(a) production and circulating Lp(a), but the Phase 3 Lp(a)HORIZON result showed that molecular target engagement did not translate into fewer major cardiovascular events.